As GlaxoSmithKline's flu vaccine manufacturing struggles in Canada continue, Sanofi is moving into the country with its own four-strain flu blocker. Its Fluzone Quadrivalent will roll out in Canada starting this flu season, it said Wednesday.
GlaxoSmithKline has submitted its plans to whip its troubled Quebec flu vaccine plant into shape to Health Canada, and the regulator says the action outline is up to snuff.
While GlaxoSmithKline is eyeing a strong performance from Fluarix Quadrivalent in its sophomore year, it may have to rely on Fluarix more than it would like if it doesn't make peace with regulators over quality issues at its FluLaval plant.
Whereas in the past, a vaccine given in August would offer little protection come February, new formulations are extending the period of immunity. Healthcare professionals have responded by adjusting the advice they give to their patients.